Investor Relations and ASX Biosciences : Part of the Problem

In the last couple of weeks we have seen a couple of interesting movements between the corporate and investor relations world, a “new” arrival and an “old” departure. Firstly, in Prima Biomed’s (ASX :PRR) most recent investment letter we quietly learned of Stuart Roberts’ departure from Prima Biomed as Head of Investor Relations, and the appointment of…

Starpharma Sensationalism

Really? REALLY? Yesterday Starpharma (ASX : SPL) announced that it had done some mouse models with a Herceptin-conjugated DEP dendrimer. It wasn’t peer reviewed data. It wasn’t an exhaustive pre-clinical package. It was just a one-off science experiment packaged up and served to retail investors as company propaganda. 20 mice. The company even states that…

ISN : iSonearlythere…

What a stupid company. I always thought it was beneath me to comment on this company, it’s truly that bad. But when I saw today’s ASX announcement about iSonea’s “second generation” wheeze monitor (a “Wheezometer” no less…), I just had to comment. Briefly. Not much more than a quick wheeze, I promise. Now, I don’t…

Keeping the flame alive…

Today, once again, Novogen announced that it has filed a couple of patents. Not received a notice of allowance or won an opposition or anything of commercial significance, but you know, just paperwork. Well done to Andrew Heaton and the team for getting some cunning new technology put down on the page – and especially a…

Dolly the sheep died young

In response to my question on yesterday’s post about Orthocell, several people forwarded me the link to a stock advert from a “publishing company” called Port Phillip Publishing. Just in case the link goes away, you can access the content here. The piece is called the “Body Hackers”. Sounds a bit more like an abattoir than a regen…

Orthosmell

Orthocell (ASX : OCC) has had two ASX “slaps” in the last month, to which the company pleaded “Schultz“. The first involved a bout of trading around the 6th of July. The second, a more detailed price query follow-up including some concerns in relation to activity on/around the 14th of July. Today we saw another…

Clinical Trial Communication Matters

Over the past few months I have poked several companies in the eye for the appalling quality of their clinical communication. I have specifically paid attention to Novogen (ASX : NRT), Benitec (ASX : BLT), Regeneus (ASX : RGS) and a few others. It is my position is that there is a consistently low quality and sensationalist ethos…